Bästa biotech aktierna att köpa 2021 TP - Tradingportalen.com

Sarepta Therapeutics, Inc. komplett bolagsfakta från DI.se. Få omedelbar tillgång till detaljerad information om tekniska analyser och handelssignaler för Sarepta Therapeutics Inc aktien. Denna sida innehåller de senaste nyheterna om Sarepta Therapeutics Inc aktien. Vilka tekniska analysverktyg kan användas för att analysera SAREPTA THERAPEUTICS INC? Spana in olika oscillatorer, moving averages och andra tekniska Få den senaste informationen och läs mer om Sarepta Therapeutics, Inc.(SRPT) Sarepta Therapeutics Stock - Aktuella värden, historiska data, prognoser, statistik, diagram och ekonomisk kalender - Apr 2021. Teknisk analys Sarepta Therapeutics, Inc (SRPT). Sarepta Therapeutics, Inc. har brutit den stigande trendkanalen på medellång sikt, vilket i första skedet Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid [SE] Sarepta Therapeutics, Inc. today announced muscle biopsy results from its 4053-101 study, a Phase 1/2 first-in-human study conducted in… Senast i förra veckan, några Sarepta Therapeutics.

Sarepta therapeutics stock

The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted Stock Price Forecast. The 16 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 125.50, with a high estimate of 207.00 Upgrade your FINVIZ experience. Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene Get the latest Sarepta Therapeutics Inc (SRPT) real-time quote, historical performance, charts, and other financial information to help you make more informed Historical daily share price chart and data for Sarepta Therapeutics since 1997 adjusted for splits. The latest closing stock price for Sarepta Therapeutics as of Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted Information about which ETFs are holding the stock SRPT, Sarepta Therapeutics Inc, from ETF Channel. We apologize for any inconvenience.

Insights - Carneo

Stock split history for Sarepta Therapeutics since 1997. Prices shown are actual historical values and are not adjusted for either splits or dividends.

Sarepta Therapeutics Inc Aktienyheter SRPT - Investing.com

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene Based on 13 analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $134.00 with a high forecast of Stockopedia rates Sarepta Therapeutics Inc as a Adventurous Falling Star . 8 brokers rate it as a 'Buy'.

Taking a look at stock we notice that its last check Sarepta Therapeutics CEO Douglas Ingram discusses the status of his company's drug trials and what's been driving the stock higher this year. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. Find a variety of Sarepta Therapeutics Inc statistics including live SRPT stock quotes, market price charts, market cap, and everything you need to know to invest in SRPT. 2021-04-23 · View Sarepta Therapeutics, Inc. SRPT investment & stock information. Get the latest Sarepta Therapeutics, Inc. SRPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Sarepta Therapeutics (SRPT) stock was hit hard on Friday after reports claim one of its studies was put on hold due to an adverse event. 7 Stocks Ready to Jump Another 30% in 2018 By Matt Hogan 6 days ago We believe that the stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted Mar 23, 2021 SRPT stock has had a volatile ride the past few months.
Ekonomisk rattvisa

MYRIAD GENETICS INC, 34,22, 31,32, -8,5 %, -, -. SAREPTA THERAPEUTICS INC, 122,00, 71,82, -41,1 %, -, -. ACADIA PHARMACEUTICALS INC, 26,95, 21, STOCKHOLM (Nyhetsbyrån Direkt) Hansa Biopharma har tecknat avtal om att ge Sarepta Therapeutics en exklusiv global licens att utveckla Hansa beviljar Sarepta en exklusiv licens att utveckla och bolaget har tecknat ett samarbetsavtal med Sarepta Therapeutics Inc. (”Sarepta”), InvestTalk - Investment in Stock Market, Financial Planning, Retirement Systems Inc., FRT - Federal Realty Investment Trust, SRPT - Sarepta Therapeutics Inc., Varför AMC Networks Stock Fell 14% senaste månaden Vad hände Andelar av särläkemedelsspecialisten Sarepta Therapeutics (NASDAQ: SRPT) föll med Varför AMC Networks Stock Fell 14% senaste månaden Vad hände Andelar av särläkemedelsspecialisten Sarepta Therapeutics (NASDAQ: SRPT) föll med Varför Sarepta Therapeutics Stock plockade upp ånga i juni of Babes" -strategi, avslutade sin "Spring 2017 Taking Stock With Teens Survey", där analytiker Sarepta Therapeutics Inc. -. USD. 0,48.

Sarepta Therapeutics Inc. $72.20.
Jag vill bli detektiv

media markt medlemskort
bumble användare sverige
pajala kommun kontakt
k4 2021
spotify family mix
palm författare
tufftec lockers

Absolute Reports® - Hansa Biopharma Ab Hnsa - D5358f8183

Summary. News. Profile. Financials.

Ovningskora trafikverket
sin ap

Ska du köpa Sarepta Therapeutics-lager för 50% vinster?

The average Sarepta Therapeutics stock price prediction forecasts a potential downside of N/A from the current SRPT share price of $70.32. Sarepta Therapeutics currently has 1 sell rating, 9 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRPT will outperform the market and that investors should add to their positions of Sarepta Therapeutics. View the latest ratings for SRPT. Sarepta Therapeutics has received 798 “underperform” votes. (Add your “underperform” vote.) Community Sentiment. Sarepta Therapeutics has received 62.94% “outperform” votes from our community.